Tag: Pancreatic Cancer

  • Rasonque pancreatic cancer drug wins FDA approval

    The Rasonque pancreatic cancer treatment from Revolution Medicines has received US Food and Drug Administration (FDA) approval for certain patients with metastatic disease. The once-daily oral medicine, also known as daraxonrasib, is approved for patients who have received previous treatment or cannot undergo combination chemotherapy. It targets several forms of the RAS protein, which plays a significant role in driving…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • mRNA Vaccines Show Promise in Personalised Therapy

    Cancer vaccines based on mRNA technology are showing encouraging results against some of the world’s hardest-to-treat cancers, including melanoma, pancreatic cancer and glioblastoma. The same technology used to develop COVID-19 vaccines at record speed is now being tested to train the immune system to recognise and destroy cancer cells. In addition, researchers say the field has become one of the…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Daraxonrasib Pancreatic Cancer Pill Doubles Survival

    A once-daily targeted tablet is reshaping expectations in one of oncology’s toughest diseases. New phase 3 data show the Daraxonrasib Pancreatic Cancer Pill nearly doubled median survival for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC), compared with standard chemotherapy. Clinicians typically identify pancreatic cancer late. Outcomes in metastatic disease have barely shifted for decades, especially after first-line chemotherapy.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Daraxonrasib Pancreatic Cancer Results: A Historic Breakthrough

    Every so often, a medical advance is so significant that it gives seasoned oncologists chills. This is currently the case for Revolution Medicines and their experimental therapy, daraxonrasib. In a recent late-stage study, the drug allowed patients with advanced disease to live twice as long as those receiving standard chemotherapy. For a field where progress is often measured in mere…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in